Ben-David U, Benvenisty NThe tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 11:268-277

Stem Cell Unit, Department of Genetics, Silberman Institute of Life Sciences, The Hebrew University, Jerusalem 91904, Israel.
Nature Reviews Cancer (Impact Factor: 37.4). 03/2011; 11(4):268-77. DOI: 10.1038/nrc3034
Source: PubMed


The unique abilities of human pluripotent stem cells to self-renew and to differentiate into cells of the three germ layers make them an invaluable tool for the future of regenerative medicine. However, the same properties also make them tumorigenic, and therefore hinder their clinical application. Hence, the tumorigenicity of human embryonic stem cells (HESCs) has been extensively studied. Until recently, it was assumed that human induced pluripotent stem cells (HiPSCs) would behave like their embryonic counterparts in respect to their tumorigenicity. However, a rapidly accumulating body of evidence suggests that there are important genetic and epigenetic differences between these two cell types, which seem to influence their tumorigenicity.

Download full-text


Available from: Uri ben-david, Sep 30, 2015
108 Reads
  • Source
    • "Accordingly, great number of scientists focus on stem cell research as an upcoming strategy in the cancer treatment process [3e5]. Of three types of stem cells, embryonic stem cells and induced pluripotent stem cells are tumorigenic [6]. Therefore , adult stem cells are the only candidate. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer treatment plans mainly include chemotherapy, radiotherapy and surgery, which exert serious adverse reactions immediately or during the long term after cancer therapy in many patients. In several cases, treatment-related adverse effects outweigh treatment benefits and worsen the patient's condition. This problem is not avoidable with current cancer therapy procedures; therefore, improved understanding and earlier prevention and reversion of treatment-related complications are particularly important before the lesions become progressive and irreversible. Mesenchymal stromal cell therapy is very promising in recent clinical research and investigations. Their potential properties such as regenerative and reparative functions and anti-inflammatory activity make them proper candidates for cell therapy to recover cancer patients from treatment-related adverse effects or may even prevent them. This article discuss benefits of applying human mesenchymal stromal cell therapy after current cancer treatment plans, with the purpose of prevention and healing of adverse reactions, faster patient recovery after radio/chemotherapy, reducing rates of treatment failure and cancer recurrence and increasing patient quality of life after treatment cessation.
    Cytotherapy 01/2015; 17(5). DOI:10.1016/j.jcyt.2014.10.015 · 3.29 Impact Factor
  • Source
    • "Biochimica et Biophysica Acta xxx (2014) xxx–xxx While cells in culture may be inherently unstable, cancer cells and pluripotent cells proliferate much faster than normal mature cell types, and — importantly — they do not senesce in culture. Therefore, these cell types are more prone to acquire genomic abnormalities, and these abnormalities may significantly increase their in vivo tumorigenicity [4]. Other factors that may make these cell types particularly vulnerable to genomic insults include unique cell cycle characteristics and DNA damage repair mechanisms, as well as cell culture practices and culture conditions (reviewed in [15]). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer cells and stem cells share many traits, including a tendency towards genomic instability. Human cancers exhibit tumor-specific genomic aberrations, which often affect their malignancy and drug response. During their culture propagation, human pluripotent stem cells (hPSCs) also acquire characteristic genomic aberrations, which may have significant impact on their molecular and cellular phenotypes. These aberrations vary in size from single nucleotide alterations to copy number alterations to whole chromosome gains. A prominent challenge in both cancer and stem cell research is to identify "driver aberrations" that confer a selection advantage, and "driver genes" that underlie the recurrence of these aberrations. Following principles that are already well-established in cancer research, candidate driver genes have also been suggested in hPSCs. Experimental validation of the functional role of such candidates can uncover whether these are bona fide driver genes. The identification of driver genes may bring us closer to a mechanistic understanding of the genomic instability of stem cells. Guided by terminologies and methodologies commonly applied in cancer research, such understanding may have important ramifications for both stem cell and cancer biology. This article is part of a Special Issue entitled: Stress as a fundamental theme in cell plasticity
    Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 08/2014; 1849(4). DOI:10.1016/j.bbagrm.2014.08.005 · 6.33 Impact Factor
  • Source
    • "The definition of pluripotency relies upon a cell’s ability to differentiate into the three embryonic germ layers, and in the case of stem cells, to self-renew [29]. Tumor formation coincides with both pluripotency and self-renewal and has emerged as a critical factor in determining the pluripotent capacities of both ES and iPS cells [30-33]. However, as seen in ES and iPS cells, the capacity for tripoblastic differentiation and self-renewal is frequently uncontrolled, and often materializes in teratoma formation, hindering the exploitation of their pluripotency for regenerative purposes. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In 2010, Multilineage Differentiating Stress Enduring (Muse) cells were introduced to the scientific community, offering potential resolution to the issue of teratoma formation that plagues both embryonic stem (ES) and induced pluripotent (iPS) stem cells. Isolated from human bone marrow, dermal fibroblasts, adipose tissue and commercially available adipose stem cells (ASCs) under severe cellular stress conditions, Muse cells self-renew in a controlled manner and do not form teratomas when injected into immune-deficient mice. Furthermore, Muse cells express classic pluripotency markers and differentiate into cells from the three embryonic germ layers both spontaneously and under media-specific induction. When transplanted in vivo, Muse cells contribute to tissue generation and repair. This review delves into the aspects of Muse cells that set them apart from ES, iPS, and various reported adult pluripotent stem cell lines, with specific emphasis on Muse cells derived from adipose tissue (Muse-AT), and their potential to revolutionize the field of regenerative medicine and stem cell therapy.
    Clinical and Translational Medicine 05/2014; 3(1):12. DOI:10.1186/2001-1326-3-12
Show more